Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 6, 2009, Pages 1888-1893

  Takai, Tetsunari ^a   Kanaoka, Shigeru ^a   Yoshida, Ken Ichi ^a   Hamaya, Yasushi ^a   Ikuma, Mutsuhiro ^a   Miura, Naoyuki ^a   Sugimura, Haruhiko ^a   Kajimura, Masayoshi ^b   Hishida, Akira ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Enshu Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; MATRILYSIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; FECES ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; EARLY DETECTION OF CANCER; FECES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SCREENING; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; NEOPLASM STAGING; OCCULT BLOOD; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 67449085949     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0937     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Number of deaths and proportional mortality rates from malignant neoplasms by site in Japan (2003) Cancer incidence, rates and age-specific rates per 100,000 population in Japan according to sex and site. In: The Editorial Board of the Cancer Statistics in Japan. Cancer Statistics in Japan-2005. Tokyo: Foundation for Promotion of Cancer Research; 2005. p. 36-37, p. 46-7.
3. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000;284:1954-1961 (Pubitemid 30778489)
4. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-1371
5. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-1471 (Pubitemid 26400241)
6. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-1477 (Pubitemid 26400242)
7. Saito H. Screening for colorectal cancer by immunochemical fecal occult blood testing. Jpn J Cancer Res 1996;87:1011-1024 (Pubitemid 26392036)
8. Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Ann Intern Med 1997;126:811-822 (Pubitemid 27209650)
9. Macrae FA, St John DJ. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 1982;82:891-898
10. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256:102-105
11. Eguchi S, Kohara N, Komuta K, Kanematsu T. Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer 1996;77:1707-1710 (Pubitemid 26111856)
12. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-1227
13. Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:858-865 (Pubitemid 32586613)
14. Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002;346:311-320 (Pubitemid 34438838)
15. Traverso G, Shuber A, Olsson L, et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002;359:403-404 (Pubitemid 34158951)
16. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-2714 (Pubitemid 39665324)
17. Davidson LA, Jiang YH, Lupton JR, Chapkin RS. Noninvasive detection of putative biomarkers for colon cancer using fecal messenger RNA. Cancer Epidemiol Biomarkers Prev1995;4:643-647
18. Alexander RJ, Raicht RF. Purification of total RNA from human stool samples. Dig Dis Sci 1998;43:2652-2658 (Pubitemid 29034919)
19. Yamao T, Matsumura Y, Shimada Y, et al. Abnormal expression of CD44 variants in the exfoliated cells in the feces of patients with colorectal cancer. Gastroenterology 1998;114:1196-1205 (Pubitemid 28243905)
20. Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 2004;127:422-427 (Pubitemid 39091890)
21. Kanaoka S, Takai T, Yoshida K. Cyclooxygenase-2 and tumor biology. Adv Clin Chem 2007;43:59-78. (Pubitemid 44960960)
22. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-1188 (Pubitemid 24294584)
23. Kawasaki T, Nosho K, Ohnishi M, et al. Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer 2008;8:33. (Pubitemid 351325426)
24. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev2004;23:101-117
25. Heslin MJ, Yan J, Johnson MR, Weiss H, Diasio RB, Urist MM. Role of matrix metalloproteinases in colorectal carcinogenesis. Ann Surg 2001;233:786-792 (Pubitemid 32494559)
26. Newell KJ, Witty JP, Rodgers WH, Matrisian LM. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 1994;10:199-206. (Pubitemid 24283035)
27. Ishikawa T, Ichikawa Y, Mitsuhashi M, et al. Matrilysin is associated with progression of colorectal tumor. Cancer Lett 1996;107:5-10. (Pubitemid 26370851)
28. Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A 1997;94:1402-1407 (Pubitemid 27087863)
29. Shattuck-Brandt RL, Lamps LW, Heppner Goss KJ, DuBois RN, Matrisian LM. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. Mol Carcinog 1999;24:177-187 (Pubitemid 29169858)
30. Boedefeld WM, II, Soong R, Weiss H, et al. E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7. Mol Carcinog 2005;43:13-17 (Pubitemid 40629198)
31. Sobin LH WCe. Intenational Union Against Cancer (UICC). TNM classification of malignant tumors. John Wiley & Sons, Inc.; 2002.
32. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994;12:725-729 (Pubitemid 24110911)
33. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002;315:157-168 (Pubitemid 33145255)
34. St John DJ, Young GP, Alexeyeff MA, et al. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 1993;104:1661-1668 (Pubitemid 23235456)
35. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-159 (Pubitemid 26017953)
36. Castiglione G, Zappa M, Grazzini G, et al. Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. Br J Cancer 1996;74:141-144 (Pubitemid 26231992)
37. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129:422-428 (Pubitemid 41096630)
38. Ahlquist DA, Wieand HS, Moertel CG, et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 1993;269:1262-1267
39. Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005;97:1124-1132 (Pubitemid 41511211)
40. Nosho K, Yoshida M, Yamamoto H, et al. Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis 2005;26:892-899
41. Erisman MD, Rothberg PG, Diehl RE, Morse CC, Spandorfer JM, Astrin SM. Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene. Mol Cell Biol 1985;5:1969-1976 (Pubitemid 15049156)